<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636022</url>
  </required_header>
  <id_info>
    <org_study_id>MinnesotaHealthSolutions</org_study_id>
    <nct_id>NCT03636022</nct_id>
    <nct_alias>NCT03856567</nct_alias>
  </id_info>
  <brief_title>Virtual Reality System for Anxiety and OCD</brief_title>
  <official_title>Low-Cost, Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and Obsessive Compulsive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minnesota HealthSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Minnesota HealthSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for&#xD;
      anxiety disorders. The investigators aim to enhance this therapy with the use of virtual&#xD;
      reality exposures. The human subjects study will test the effects of using VR for exposures&#xD;
      compared to traditional imaginal exposures on anxiety symptom improvement, functioning, child&#xD;
      engagement in an response to exposures, completion of exposure homework between treatment&#xD;
      sessions, and length of treatment in weeks and length of treatment among children with&#xD;
      anxiety disorders and/or obsessive compulsive disorder.&#xD;
&#xD;
      The funding award supports the development of the technology and the human subjects study.&#xD;
      The subcontract to Mayo supports expert input to identify clinically relevant content for&#xD;
      therapeutic videos on the VR system and the human subjects study to test the VR system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seventy children with childhood anxiety disorders (CADs) or obsessive compulsive disorder&#xD;
      (OCD) and a parent will be recruited to test the Phase II VR system with a randomized&#xD;
      controlled mixed methods study. Participants will be identified through the Mayo Clinic&#xD;
      Pediatric Anxiety Disorders Clinic (PADC). Participants will be randomly assigned to home&#xD;
      exposure practice with or without the VR system, i.e., intervention or control, respectively.&#xD;
      All participants in the study will participate in an introductory session in which&#xD;
      participants complete two exposures related to content from their fear ladder, one with the&#xD;
      VR system and analogous imaginal exposure. Each family will receive instructions for how to&#xD;
      use the Mayo Clinic Anxiety Coach tablet app to record exposures during home practice.&#xD;
      Participants will then be assigned one week of daily exposure homework for the intervention&#xD;
      and control conditions. Participants randomized to the intervention condition will take home&#xD;
      the VR system for homework completion and participants assigned to control will be instructed&#xD;
      to complete imaginal exposures. One week after the introductory session, all participants&#xD;
      will return for a session in which participants complete both types of exposure. Participants&#xD;
      will also be assigned to a third generalization exposure, i.e., an exposure related to the&#xD;
      baseline exposure that is higher on the fear ladder, to complete at their next anxiety clinic&#xD;
      treatment sessions. SUDS ratings for each type of exposure will be recorded electronically&#xD;
      via the Mayo Clinic Anxiety Coach. During the follow up session, an independent interviewer&#xD;
      will observe participants' engagement during exposure and will interview participants and&#xD;
      their parents about their experience with both types of exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to home exposure practice with or without the VR system, i.e., intervention or control</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Subjective Units of Distress Scale (SUDS) at end of session</measure>
    <time_frame>2 hours</time_frame>
    <description>The SUDS - 0 to 10 ratings, where 0 indicates that participants feel no anxiety at all and 10 indicates that participants are experiencing maximum distress.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anxiety</condition>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>VR System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will then be assigned one week of daily exposure homework. Patients randomized to the intervention condition will take home the VR system for homework.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will then be assigned one week of daily exposure homework. Participants assigned to control will be instructed to complete imaginal exposures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VR System</intervention_name>
    <description>Use of virtual reality to deliver exposure therapy</description>
    <arm_group_label>VR System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Use of conventional delivery of exposure therapy</description>
    <arm_group_label>Control Condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 7 to 17&#xD;
&#xD;
          2. Primary diagnosis of an anxiety disorder or obsessive compulsive disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of and/or current diagnosis of: psychosis, autism, bipolar disorder, mental&#xD;
             retardation, oppositional defiant disorder, PTSD, selective mutism or major depressive&#xD;
             disorder.&#xD;
&#xD;
          2. Current sucidality or recent suicidal behavior.&#xD;
&#xD;
          3. Parent to be involved in study who is unable to adequately participate due to&#xD;
             intellectual or psychiatric difficulties.&#xD;
&#xD;
          4. Starting or changing the dosage of psychiatric medications in the last 2 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget Biggs, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deanna R Hofschule</last_name>
    <phone>507-255-2972</phone>
    <email>hofschulte.deanna@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bridget K Biggs, Ph.D., L.P.</last_name>
    <phone>507-255-2972</phone>
    <email>biggs.bridget@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna R. Hofschulte</last_name>
      <phone>507-255-2972</phone>
      <email>hofschulte.deanna@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bridget K. Biggs, Ph.D., L.P.</last_name>
      <phone>507-255-2972</phone>
      <email>biggs.bridget@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>OCD</keyword>
  <keyword>Obsessive Compulsive Disorder</keyword>
  <keyword>Generalized Anxiety Disorder</keyword>
  <keyword>Social Phobia</keyword>
  <keyword>Separation Anxiety</keyword>
  <keyword>GAD</keyword>
  <keyword>Youth</keyword>
  <keyword>Teen</keyword>
  <keyword>Therapy</keyword>
  <keyword>Specific Phobia</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be made available through the National Database for Clinical Trials Related to Mental Illness</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>6 months following the study completion</ipd_time_frame>
    <ipd_access_criteria>To be determined by the National Institute of Mental Health</ipd_access_criteria>
    <ipd_url>http://ndct.nimh.nih.gov</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

